DeutschNewstral
Article
Mmarketwatch.com on 2015-09-17 14:28
Can-Fite Bio shares surge about 40% as liver drug gets FDA fast track designation
Related news
Loxo Oncology treatment earns FDA special designationwestfaironline.com
SA biotech gets FDA orphan drug designationbizjournals.com- MediBeacon device earns ‘breakthrough’ designation from FDAbizjournals.com
FDA Talks Regenerative Medicine Advanced Therapy Designationjdsupra.com- HFDA designation 'really big deal' for Athersyshome.crainscleveland.com
- FDA grants Cary's Chiesi new designationbizjournals.com
Shreis Scalene Sciences gets FDA ‘breakthrough’ designationthedailyrecord.com- MBeiGene drug gets 'breakthrough therapy' designation from FDAmarketwatch.com
- Novavax gets FDA fast track designation for flu vaccinethedailyrecord.com
- MGenprex's stock rallies on FDA fast-track designationmarketwatch.com
FDA Grants Breakthrough Device Designation To VR Mental Illness TreatmentForbes
Digital therapy program for fibromyalgia receives FDA breakthrough device designationTechCrunch- MIovance shares jump on FDA cancer drug fast-track designationmarketwatch.com
- MAcadia shares rise on FDA dementia drug designationmarketwatch.com
- Adaptimmune gets FDA designation to accelerate development of cancer therapybizjournals.com
- Special FDA designation puts more wind behind BioCryst's sailsbizjournals.com
- FDA Unveils Considerations for Rescinding Breakthrough Therapy Designationjdsupra.com
Celcuity secures FDA 'breakthrough therapy designation' for breast cancer drugStar Tribune- Sapience Therapeutics ST-36 receives orphan drug designation from FDAwestfaironline.com
- FDA grants special designation for Bayer AI softwarebizjournals.com